References
- Cohen JP, Bridges JFP. Assessing comparative effectiveness research in the US. Appl. Health Econ. Health Policy7(4), 219–224 (2009).
- Bridges JFP, Onukwugha E, Mullins CD. Healthcare rationing by proxy: cost–effectiveness analysis and the misuse of the $50,000 threshold in the US. Pharmacoeconomics28(3), 175–184 (2010).
- Bridges JFP, Cohen JP, Grist PG, Mühlbacher AC. International experience with comparative effectiveness research: case studies from England/Wales and Germany. Advances in Health Economics and Health Services Research. Emerald Group Publishing Limited, Bingley, UK 29–50 (2010).
- Orszag PR, Ellis P. Addressing rising health care costs: the view from the congressional budget office. N. Engl. J. Med.357(19), 1885–1887 (2007).
- Neumann PJ, Greenberg D. Is the United States ready for QALYs? Health Affairs28(5), 1366–1371 (2009).
- Clement FM, Harris A, Li JJ, Yong K, Lee KM, Manns BJ. Using effectiveness and cost-effectiveness to make drug coverage decisions: a comparison of Britain, Australia and Canada. JAMA302(13), 1432–1443 (2009).
- Chalkidou K, Tunis S, Lopert R et al. Comparative effectiveness research and evidence-based health policy: experience from four countries. The Millbank Quarterly87(2), 339–367 (2009).
- Collins FS. Opportunities for research and NIH. Science327(5961), 36–37 (2010).
- Laugharne R, Priebe S. Trust, choice and power in mental health. Soc. Psychiatry Psychiatr. Epidemiol.41, 843–852 (2006).
- Bridges JF. Stated preference methods in health care evaluation: an emerging methodological paradigm in health economics. Appl. Health Econ. Health Policy2(4), 213–224 (2003).
- Hetrzman C, Frank J, Evans R. Heterogeneities in health status and the determinants of population health. In: Why Are Some People Healthy and Others Not? The Determinants of Health of Populations. Evans R, Barer M, Marmor T (Eds). Alsine de Gruyter, NY, USA 67–92 (1994).
- Williams A. Inequalities in health and intergenerational equity. Ethical Theory Moral Pract.2(1), 47–55 (1999).
- Arnesen T, Trommald M. Are QALYs based on time trade-offs comparable? A systematic review of TTO methodologies. Health Econ.14(1), 39–53 (2005).
- Brazier JE, Dixon S, Ratcliffe J. The role of patient preferences in cost-effectiveness analysis: a conflict of values? Pharmacoeconomics27(9), 705–712 (2009).
- Mason H, Baker R, Donaldson C. Willingness to pay for a QALY: past, present and future. Expert Rev. Pharmacoecon. Outcomes Res.8(6), 575–582 (2008).
- Ryan M. Using conjoint analysis to take account of patient preferences and go beyond health outcomes: an application to in-vitro fertilization. Soc. Sci. Med.48, 535–546 (1999).
Websites
- Department of Health and Human Services. Text of the recovery act related to comparative effectiveness funding: the American Recovery and Reinvestment Act (2009) www.hhs.gov/recovery/programs/cer/recoveryacttext.html
- Institutes of Medicine. Report brief: initial national priorities for comparative effectiveness research www.iom.edu/cerpriorities